Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSZ102 Monotherapy or Combination in ER+ Breast Cancer
NCT02734615Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jun 2016
- Primary completion
- Sep 2021
- Modality
- Molecular Glues
- Countries
- 7
01
Overview
Phase 1, open-label trial of LSZ102 in breast cancer, sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities and Safety and tolerability of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719 at 3 years. Started Jun 2016; status: terminated.
02
Drugs
LSZ102
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02734615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02734615.